Phytohealth Corporation · TWSE:4108
Phytohealth — 2024 Institutional Investor Conference
27 slides from Phytohealth's conference presentation, September 2024
Slide 1: Phytohealth Corporation
Phytohealth Corporation Taiwan Stock Exchange (symbol:4108) 2024 Institutional Investor Conference Established: 1998 Stock Exchange Listed: 2008 Capitalization: USD 70M Chairperson: Yili Lee CEO Angel Lee
Slide 2: Statement
Statement 1.Apart from historical data, the matters listed in this presentation that are forward-looking statements may be subject to significant risks and uncertainties, which could result in differences between these forward-looking statements and actual outcomes. 2.The future projections presente
Slide 3: Company Profile
Company Profile i T_T 2, REA DAD PhytoHealth Corporation
Slide 4: Applying drug development techniques to botanical medicine
PhytoHealth aims to apply the latest pharmaceutical drug development techniques to innovate natural treatments used for thousands of years in Chinese botanical medicine practices to satisfy the unmet clinical needs.
Slide 5: Key milestones of Phytohealth Corporation
Key milestones of Phytohealth Corporation Company 1998 established 2002 Company public listing Listed on OTC as the first new drug R&D company 2008 • 1st botanical drug NDA • 1st oral nalbuphine received approval (PG2®) • API manufacturing factory NDA approval (Oraphine®) • Completion of Botanical a
Slide 6: New drug product development: 2 items have TFDA drug licenses
Phytohealth's new drug product development: 2 items have obtained TFDA drug licenses Product Function / Indication Pre-Clinical Phase I Phase II Phase III NDA Approval 懷特血寶® The world's only prescription drug to treat PG2 "Cancer Related Fatigue" 上 市 懷特痛寶® New analgesic (Nalbuphine) oral dosage form
Slide 7: Global botanical and plant-derived drugs market
The global market for USD in 2024 botanical and plant-derived drugs has show continual growth over the last decade and is showing promise to continue moving forward at steady pace. USD by 2030 *Botanical and Plant-derived Drugs: Global CAGR Markets, BCC Research
Slide 8: Key factors holding back botanical drug markets
Key factors holding back botanical drug markets Botanical Drug Guidance 1 2 Sufficient efficacy Key factors 3 Market traction
Slide 9: Our Track Record of Success
Our Track Record of Success Regulatory Evidence of Market Growth Approval Efficacy 1st New TFDA License 24 Research Articles PG2 is reimbursed by Taiwan For Prescription Botanical on PG2 found in top 25% National Health issuance. the1st Drug issued by TFDA Leading Medical & Cancer botanical drug rei
Slide 10: Sharing our Value Chain
Sharing our Value Chain R&D - Unmet Need in oncology, anti- COVID-19..etc Manufacturing PhytoHealth’s API Plant awarded with PIC/S RWE GMP Certificate - Data generation & Publication - CME program Sales & Marketing - Market Access strategy: self –pay & reimbursement - Focus on Hospital Channel - Pat
Slide 11: 2023-2024 Key progress
i im. Pe E on”, 2023-2024 Key pr | (7, 25 20H PhytoHealth Corporation
Slide 12: PG2 overall survival study in esophageal cancer
1. The results of the study on the prolongation of overall survival (Overall Survival) of patients with locally advanced esophageal cancer using PG2 Combination with preoperative Chemoradiotherapy. Published at 2024 ESMO (European Society of Clinical Oncology)
Slide 13: Published at ESMO Annual Meeting in September 2024
Published at ESMO Annual Meeting in September 2024 Clinical test： • Period：02.19.2019-02.06.2025 • Hospital：Ma Kai, Sanzong, Yadong, Shuanghe • Case received：48 • Assessable：38 Can regulate the cancer immune microenvironment To effectively improve the overall survival rate Conclusion: 「CRF」Drug comb
Slide 14: 2024 PG2 Domestic and International Academic Publishing
2024 PG2 Domestic and International Academic Publishing [PG2 合併化療於大腸直腸癌病患RWE] [PG2 健保乳癌RWE臨床效益] 14
Slide 15: Strengthen clinical decision making in Cancer-Related Fatigue
2. Strengthen clinical decision making in Cancer-Related Fatigue
Slide 16: 92% of patients have cancer-related fatigue
92% of patients have cancer-related fatigue According to the "Guidelines of Management of Cancer related Fatigue1” Astragals polysaccharide injection (PG2® ) is recommended to treat moderate to sever cancer related fatigue (Level 1A, Grade A Recommendation ) 1. Management of Cancer Related Fatigue i
Slide 17: Strengthen decision-making for CRF
Strengthen decision-making for CRF Medical Association Continuing Education Patient RWE Group CRF R53.0* (CRF, Cancer Related Fatigue)
Slide 18: Launch Oraphine Globally
3. Launch Oraphine®Globally
Slide 19: Oraphine - A Novel Oral Analgesic
Oraphine ® - A Novel Oral Analgesic For Moderate to Severe Pain Management Source : Summarized by PHC team
Slide 20: Oraphine 60mg Soft Capsule for moderate to severe pain
Oraphine®60mg@soft Capsule : The ideal choice to treat moderate to severe pain Oraphine® is the first choice of oral analgesia for moderate to severe pain because it provides rapid onset, powerful efficacy and better safety profile. • Now in use in major hospitals in Taiwan 20
Slide 21: Enter health care with the spirit of new drug R&D
4. Enter health care with the spirit of new drug research and development
Slide 22: Western medicine, Traditional Chinese medicine, health care
Western medicine clinical Traditional Chinese medicine health care Food supplement concept
Slide 23: Indena S.p.A: MOU to advance into the international market
Indena S.p.A : Signing of MOU to advance into the international market The signing of MOU and MTA 2024.2 between both parties was completed The two parties will jointly develop the plant extract raw materials developed by Phytohealth ，Indena will assist in the subsequent EU inspection and regist
Slide 24: Financial information
Financial information ST ¢, PSE Rese) AG) PhytoHealth Corporation
Slide 25: Balance Sheet
Sound financial structure 1. Sufficient cash 「Balance Sheet」 2. Low debts ratio (Expressed in Thousands of New Taiwan Dollars) Account 113.6.30 % 112.12.31 % CURRENT ASSETS 1,449,068 62 1,499,456 64 NON-CURRENT 895,190 38 851,055 36 TOTAL ASSETS 2,344,258 100 2,350,511 100 CURRENT LIABILITIES 48,863
Slide 26: Income statement
1.Net sales grew 6% 2.The increase in exp. is due to investment in 「Income statement」 research and development projects (Expressed in Thousands of New Taiwan Dollars) 113 1-6 112 1-6 +-% Account (A) % (B) % (A-B)/B Net Sales 76,713 100 72,370 100 6 Gross Margin 30,161 39 29,590 41 2 Operating Exp. (
Slide 27: 27
27